Profiling the Structural Determinants for the Selectivity of Representative Factor-Xa and Thrombin Inhibitors Using Combined Ligand-Based and Structure-Based Approaches
暂无分享,去创建一个
[1] B. Bhongade,et al. 3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis. , 2005, Bioorganic & medicinal chemistry.
[2] D. Davey,et al. Structure-activity relationships of substituted benzothiophene-anthranilamide factor Xa inhibitors. , 2003, Bioorganic & medicinal chemistry letters.
[3] Anshuman Dixit,et al. An investigation of structurally diverse carbamates for acetylcholinesterase (AChE) inhibition using 3D-QSAR analysis. , 2008, Journal of molecular graphics & modelling.
[4] G. Lip,et al. Apixaban, an oral, direct inhibitor of activated Factor Xa. , 2008, Current opinion in investigational drugs.
[5] R. Huber,et al. Crystal structures of factor Xa specific inhibitors in complex with trypsin: structural grounds for inhibition of factor Xa and selectivity against thrombin , 1995, FEBS letters.
[6] Bin Ye,et al. Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors. , 2007, Journal of medicinal chemistry.
[7] M. Bock,et al. Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position. , 1997, Journal of medicinal chemistry.
[8] R. Huber,et al. Structure of human des(1-45) factor Xa at 2.2 A resolution. , 1993, Journal of molecular biology.
[9] Daniel L Cheney,et al. Optimization of the beta-aminoester class of factor Xa inhibitors. Part 2: Identification of FXV673 as a potent and selective inhibitor with excellent In vivo anticoagulant activity. , 2002, Bioorganic & medicinal chemistry letters.
[10] G. Klebe,et al. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.
[11] J. Weitz,et al. New Antithrombotic Drugs , 2009, Clinical pharmacology and therapeutics.
[12] A. Spada,et al. Crystal structures of human factor Xa complexed with potent inhibitors. , 2000, Journal of medicinal chemistry.
[13] Gerhard Klebe,et al. Comparative Molecular Similarity Index Analysis (CoMSIA) to study hydrogen-bonding properties and to score combinatorial libraries , 1999, J. Comput. Aided Mol. Des..
[14] M. Adler,et al. Substituted thiophene-anthranilamides as potent inhibitors of human factor Xa. , 2007, Bioorganic & medicinal chemistry.
[15] Gyanendra Pandey,et al. 3D QSAR Studies on Protein Tyrosine Phosphatase 1B Inhibitors: Comparison of the Quality and Predictivity among 3D QSAR Models Obtained from Different Conformer-Based Alignments , 2006, J. Chem. Inf. Model..
[16] Hans Matter,et al. Design and quantitative structure-activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa. , 2002, Journal of medicinal chemistry.
[17] Anil K. Saxena,et al. Consensus Superiority of the Pharmacophore-Based Alignment, Over Maximum Common Substructure (MCS): 3D-QSAR Studies on Carbamates as Acetylcholinesterase Inhibitors , 2009, J. Chem. Inf. Model..
[18] H. Kubinyi,et al. 3D QSAR in drug design. , 2002 .
[19] Hans Matter,et al. Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: combining X-ray crystallography, 3D-QSAR, and tailored scoring functions. , 2005, Journal of medicinal chemistry.
[20] S. Kunitada,et al. Molecular model of an interaction between factor Xa and DX-9065a, a novel factor Xa inhibitor: Contribution of the acetimidoylpyrrolidine moiety of the inhibitor to potency and selectivity for serine proteases , 1995 .
[21] H. Nar,et al. Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors. , 2001, Structure.
[22] G Klebe,et al. Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. , 1999, Journal of medicinal chemistry.
[23] Robert Huber,et al. X-ray Structure of Active Site-inhibited Clotting Factor Xa , 1996, The Journal of Biological Chemistry.
[24] G Klebe,et al. Factorising ligand affinity: a combined thermodynamic and crystallographic study of trypsin and thrombin inhibition. , 2001, Journal of molecular biology.
[25] S. Haas. New anticoagulants - towards the development of an "ideal" anticoagulant. , 2009, VASA. Zeitschrift fur Gefasskrankheiten.
[26] Mika A. Kastenholz,et al. GRID/CPCA: a new computational tool to design selective ligands. , 2000, Journal of medicinal chemistry.
[27] Lawrence C Kuo,et al. Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitors. , 2004, Journal of medicinal chemistry.
[28] A. Ortiz,et al. Comparative binding energy analysis considering multiple receptors: a step toward 3D-QSAR models for multiple targets. , 2006, Journal of medicinal chemistry.
[29] Angelo Carotti,et al. An Integrated Approach to Ligand- and Structure-Based Drug Design: Development and Application to a Series of Serine Protease Inhibitors , 2008, J. Chem. Inf. Model..
[30] F. Diederich,et al. Cation-pi interactions at the active site of factor Xa: dramatic enhancement upon stepwise N-alkylation of ammonium ions. , 2009, Angewandte Chemie.
[31] B. Xin,et al. Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits , 2009, Journal of thrombosis and haemostasis : JTH.
[32] D. Cheney,et al. Factor Xa inhibitors: next-generation antithrombotic agents. , 2010, Journal of medicinal chemistry.
[33] Maj Schuster,et al. From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3. , 2007, Bioorganic & medicinal chemistry letters.
[34] Sung-Hou Kim,et al. Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa. , 2000, Biochemistry.
[35] C. Chang,et al. Unexpected binding mode of tick anticoagulant peptide complexed to bovine factor Xa. , 1998, Journal of molecular biology.
[36] Anil K. Saxena,et al. Structural Basis for the β-Adrenergic Receptor Subtype Selectivity of the Representative Agonists and Antagonists , 2011, J. Chem. Inf. Model..
[37] J. Ansell. Factor Xa or thrombin: is factor Xa a better target? , 2007, Journal of thrombosis and haemostasis : JTH.
[38] Sung-Hou Kim,et al. Structural basis for chemical inhibition of human blood coagulation factor Xa. , 1998, Proceedings of the National Academy of Sciences of the United States of America.